Activating SRC mutation in a subset of advanced human colon cancers
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The discovery of Rous sarcoma virus (RSV) led to the identification of cellular Src (c-Src), a non-receptor tyrosine kinase, which has since been implicated in the development of numerous human cancers. c-Src has been found to be highly activated in colon cancers, particularly in those metastatic to the liver. Studies of the mechanism of c-Src regulation have suggested that c-Src kinase activity is downregulated by phosphorylation of a critical carboxy-terminal tyrosine (Tyr 530 in human c-Src, equivalent to Tyr 527 in chicken Src) and have implied the existence of activating mutations in this C-terminal regulatory region. We report here the identification of a truncating mutation in SRC at codon 531 in 12% of cases of advanced human colon cancer tested and demonstrate that the mutation is activating, transforming, tumorigenic and promotes metastasis. These results provide, for the first time, genetic evidence that activating SRC mutations may have a role in the malignant progression of human colon cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
CELLULAR FUNCTIONS REGULATED BY SRC FAMILY KINASES
Thomas, S. M., & Brugge, J. S. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.513 · Cited by 2,498
Three-dimensional structure of the tyrosine kinase c-Src
Xu, W., Harrison, S. C., & Eck, M. J. (1997) · Nature · doi:10.1038/385595a0 · Cited by 1,418
DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA
STEHELIN, D., VARMUS, H. E., BISHOP, J. M., & VOGT, P. K. (1976) · Nature · doi:10.1038/260170a0 · Cited by 1,321 · cited 1×
“We targeted this region for mutational screening because it is known to contain the principal regulatory phosphotyrosine (Tyr 530; Ref”
BackgroundIdentification of a transformation-specific antigen induced by an avian sarcoma virus
BRUGGE, J. S., & ERIKSON, R. L. (1977) · Nature · doi:10.1038/269346a0 · Cited by 888
Kmiecik, T. E., & Shalloway, D. (1987) · Cell · doi:10.1016/0092-8674(87)90756-2 · Cited by 623
Tyr 527 Is Phosphorylated in pp60 c- src : Implications for Regulation
Cooper, J. A., Gould, K. L., Cartwright, C. A., & Hunter, T. (1986) · Science · doi:10.1126/science.2420005 · Cited by 540 · cited 1×
“We targeted this region for mutational screening because it is known to contain the principal regulatory phosphotyrosine (Tyr 530; Ref”
BackgroundThe when and how of Src regulation
Cooper, J. A., & Howell, B. (1993) · Cell · doi:10.1016/0092-8674(93)90634-3 · Cited by 533
Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src
Piwnica-Worms, H., Saunders, K. B., Roberts, T. M., Smith, A. E., & Cheng, S. H. (1987) · Cell · doi:10.1016/0092-8674(87)90757-4 · Cited by 520
Cell Transformation by the Viral src Oncogene
Jove, R., & Hanafusa, H. (1987) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.03.110187.000335 · Cited by 401
Self-citationIncrease in activity and level of pp60c-src in progressive stages of human colorectal cancer.
Talamonti, M. S., Roh, M. S., Curley, S. A., & Gallick, G. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116200 · Cited by 399
Cited by
Items 201–300 of 507
Structural metamorphism and polymorphism in proteins on the brink of thermodynamic stability
Kulkarni, P., Solomon, T. L., He, Y., Chen, Y., Bryan, P. N., & Orban, J. P. (2018) · Protein Science · doi:10.1002/pro.3458 · Cited by 47
“For example, the high affinity Bin1-SH3 binding site of Myc (1-88) consists of an”
BackgroundInfluentialSrc inhibitors: genomics to therapeutics
Sawyer, T. K., Boyce, B. F., Dalgarno, D. C., & Iuliucci, J. D. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.7.1327 · Cited by 50
“Elevated Src expression or activity has been correlated with tumour growth in specific cancers having ErbB2 or cMet receptors [2,36,37], by studies using Src-specific antisense DNA [48,49], and the recent identification of activating Src mutations in advanced human colon cancer [50].”
BackgroundBjorge, J. D., Pang, A., Funnell, M., Chen, K. Y., Diaz, R., Magliocco, A. M., & Fujita, D. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019309 · Cited by 46
“colon, ovary, prostate, and pancreas [3,4,9–12] and in melanomas”
BackgroundSelf-citationBaisden, J. M., Gatesman, A., Cherezova, L., Jiang, B., & Flynn, D. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204802 · Cited by 47
“…into rosettelike structures, and the formation of lamellipodia and ®lopodia, which are associated with increased cell motility and the onset of tumor metastasis in humans (Bolen et al., 1987; Boschek et al., 1981; Cartwright et al., 1990; Irby et al., 1999; Rosen et al., 1986; Tarone et al., 1985).”
BackgroundRégnauld, K., Nguyen, Q., Vakaet, L. C., Bruyneel, E. A., Launay, J., Endo, T., Mareel, M. M. K., Gespach, C. P., & Emami, S. (2002) · Oncogene · doi:10.1038/sj.onc.1205498 · Cited by 47
“Overexpression and activating mutations of the tyrosine kinase src are critical and frequent molecular defects involved its oncogenic action during colon cancer progression (Talamonti et al., 1993; Irby et al., 1999).”
BackgroundBasis and Importance of SRC as a Target in Cancer
Levin, V. A. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-7847-1_6 · Cited by 53
Burkhardt, J., Blume, M., Petit, É., TEIXEIRA, V. H., Steiner, A., Quente, E., Wolfram, G., Scholz, M. R., Pierlot, C., Migliorini, P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103872 · Cited by 45
Micro RNA ‐27b suppresses tumor progression by regulating ARFGEF 1 and focal adhesion signaling
Matsuyama, R., Okuzaki, D., Okada, M., & Oneyama, C. (2015) · Cancer Science · doi:10.1111/cas.12834 · Cited by 48
Intratumoral heterogeneity of intrahepatic cholangiocarcinoma
Walter, D. H., Döring, C., Feldhahn, M., Battke, F., Hartmann, S., Winkelmann, R., Schneider, M., Bankov, K., Schnitzbauer, A. A., Zeuzem, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14844 · Cited by 45
Kalishwaralal, K., Sheikpranbabu, S., BarathManiKanth, S., Haribalaganesh, R., Pandian, S. R. K., & Gurunathan, S. (2010) · Angiogenesis · doi:10.1007/s10456-010-9193-x · Cited by 46
“It was reported that Src protein levels and Src kinase activity were significantly elevated in human breast, colon, and pancreatic cancers [44].”
BackgroundRetractedZhong, M., Lu, Z., & Foster, D. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205165 · Cited by 45
“Activating mutations within the Src gene have been reported in late stage colon cancer (Irby et al., 1999; Irby and Yeatman, 2000).”
BackgroundPotential Molecular Mechanism for c-Src Kinase-mediated Regulation of Intestinal Cell Migration
Mathew, S., George, S. P., Wang, Y., Siddiqui, M. R., Srinivasan, K., Tan, L., & Khurana, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801319200 · Cited by 44
Daigo, Y., Furukawa, Y., Kawasoe, T., Ishiguro, H., Fujita, M., Sugai, S., Nakamori, S., Liefers, G., Tollenaar, R. A. �. �., van de Velde, C. J., et al. (1999) · PubMed · Cited by 64
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
Algazi, A. P., Weber, J. S., Andrews, S., Urbas, P., Münster, P. N., DeConti, R. C., Hwang, J. H., Sondak, V. K., Messina, J. L., McCalmont, T. H., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.514 · Cited by 43
“Src activation has been implicated in the pathogenesis of colon (Irby et al, 1999; Kline et al, 2008), lung (Song et al, 2006), pancreas (Trevino et al, 2006), breast (Hiscox et al, 2006; Jallal et al, 2007; Morgan et al, 2009), and prostate cancer (Nam et al, 2005; Kotha et al, 2006).”
BackgroundArcaroli, J. J., Quackenbush, K. S., Powell, R. W., Pitts, T. M., Spreafico, A., Varella‐Garcia, M., Bemis, L., Tan, A. C., Reinemann, J. M., Touban, B. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3167 · Cited by 45
“Although activating mutations in Src are rare or nonexistent (19), dysregulationof Src has been shown tobe important at early stages of cancer development and perhaps even more important during later stages of the disease (13, 20–22).”
BackgroundThe (Patho)Biology of SRC Kinase in Platelets and Megakaryocytes
Kock, L. D., & Freson, K. (2020) · Medicina · doi:10.3390/medicina56120633 · Cited by 42
“Pathogenic somatic SRC variants disturbing the SH2–Y530 interaction result in continuous SRC activation as found in colon and endometrial cancer [9,10].”
BackgroundLiu, S.-H., Lin, C., Liang, F.-P., Chen, P., Kuo, C., Alam, M. M., Maiti, B., Hung, S., Chi, C., Sun, C., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.014 · Cited by 42
“Src531 is a C-terminally truncated Src mutant previously identified in human colon cancer cells [37].”
BackgroundThe homeobox gene CDX2 in colorectal carcinoma: a genetic analysis
Sivagnanasundaram, S., ISLAM, I., Talbot, I. C., Drummond, F., Walters, J. R. F., & Edwards, Y. H. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1544 · Cited by 42
“Mutations in sever other candidate genes, such as the serine/threonine kinase STK11 (Dong et al, 1998) and the tyrosine kinase c-SRC(Irby et al, 1999) are also thought to be predisposing factors in sporadic CRC.”
BackgroundA Growth-suppressive Function for the c-Fes Protein-Tyrosine Kinase in Colorectal Cancer
Delfino, F. J., Stevenson, H. M., & Smithgall, T. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507331200 · Cited by 42
Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients
Laghi, L., Bianchi, P., Orbetegli, O., Gennari, L., Roncalli, M., & Malesci, A. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1560 · Cited by 42
“In their original report, Irby et al (1999) found high levels c-Src protein kinase activity in tissues positive at mutat analysis, but they did not preselect tissues on this b Therefore, the absence of mutations in our consecutive seri late-stage colorectal cancers and liver metastases cannot b ©…”
BackgroundInfluentialBirner, P., Gatterbauer, B., Oberhuber, G., Schindl, M., Rössler, K., Prodinger, A., Budka, H., & Hainfellner, J. A. (2001) · Cancer · doi:10.1002/1097-0142(20010701)92:1<165::aid-cncr1305>3.0.co;2-f · Cited by 195
Wang, N. M., Yeh, K.-T., Tsai, C.-H., Chen, S.-J., & Chang, J. (2000) · Cancer Letters · doi:10.1016/s0304-3835(99)00398-5 · Cited by 41
An Alternative, Human SRC Promoter and Its Regulation by Hepatic Nuclear Factor-1α
Bonham, K., Ritchie, S. A., Dehm, S. M., Snyder, K., & Boyd, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004882200 · Cited by 41
Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer
Sarries, C., Haura, E. B., Roig, B., Tarón, M., Abad, A., Scagliotti, G. V., & Rosell, R. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.6.763 · Cited by 42
Mutation of the SRC Gene in Endometrial Carcinoma
Sugimura, M., Kobayashi, K., Sagae, S., Nishioka, Y., Ishioka, S., Terasawa, K., Tokino, T., & Kudo, R. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00958.x · Cited by 37
v-Src-dependent Down-regulation of the Ste20-like Kinase SLK by Casein Kinase II
Chaar, Z. Y., O'Reilly, P., Gelman, I. H., & Sabourin, L. A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605665200 · Cited by 39
Soeda, S., Nakayama, Y., Honda, T., Aoki, A., Tamura, N., Abe, K., Fukumoto, Y., & Yamaguchi, N. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.02.023 · Cited by 48
de Jesus, A. A., Chen, G., Yang, D., Brdička, T., Ruth, N. M., Bennin, D. A., Cebecauerová, D., Malcová, H., Freeman, H., Martin, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36941-y · Cited by 40
Ali, N., Yoshizumi, M., Fujita, Y., Izawa, Y., Kanematsu, Y., Ishizawa, K., Tsuchiya, K., Yano, S., Sone, S., & Tamaki, T. (2005) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0040850 · Cited by 38
Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCδ
Yamaguchi, K., Richardson, M. D., Bigner, D. D., & Kwatra, M. M. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-1030-3 · Cited by 38
“More recently, an activating mutation in Src was revealed in a subset of advanced human colon cancers [27].”
Hofmann, A., Plachý, J., Hunt, L., Kaufman, J., & Hala, K. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00516-4 · Cited by 38
Molecular Dissection of AKT Activation in Lung Cancer Cell Lines
Guo, Y., Du, J., & Kwiatkowski, D. J. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0558 · Cited by 41
“This mutation results in truncation and deregulated activation of the SRC protein, but is rare, being seen in only 1% of all colorectal cancer and never reported in other common malignancies (42).”
Kostyniuk, C. L., Dehm, S. M., Batten, D., & Bonham, K. (2002) · Oncogene · doi:10.1038/sj.onc.1205787 · Cited by 42
“Most recently, activating and transforming mutations in the SRC gene were identified in a small percentage of advanced colon tumors (Irby et al., 1999).”
BackgroundChou, M. T.-H., Anthony, J., Bjorge, J. D., & Fujita, D. (2010) · Genes & Cancer · doi:10.1177/1947601910366719 · Cited by 37
“Furthermore, Src has been shown to be activated by a mutation resulting in truncation of the Src protein in a subset of advanced metastatic colon carcinomas.(5) Elevated Src activity has been reported to upregulate vascular endothelial growth factor (VEGF) production in several normal and tumorigenic cells types.”
BackgroundSelf-citationBarraclough, J., Hodgkinson, C. L., Hogg, A., Dive, C., & Welman, A. (2007) · Neoplasia · doi:10.1593/neo.07442 · Cited by 43
“Analogous mutations in c-Src resulted in a constitutively active open conformation of the protein [23,24]; thus, we expected c-YesY537F and c-YesDt6aa mutants to be constitutively active.”
BackgroundBrain Metastases from Colorectal Cancer: Microenvironment and Molecular Mechanisms
Zang, Y.-W., Gu, X., Xiang, J., & Chen, Z. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131215784 · Cited by 40
“[45] first demonstrate Src is an oncogene in CRC.”
BackgroundSrivastava, K., Pickard, A., McDade, S., & McCance, D. J. (2017) · Oncotarget · doi:10.18632/oncotarget.3892 · Cited by 28
“com/oncotarget of the C-terminal negative regulatory Tyr530 site, as point mutations or loss of C-terminal residues results in constitutively active Src, which is often seen in colon cancers patients [12, 13].”
BackgroundA Review of Kinases Implicated in Pancreatic Cancer
Giroux, V., Dagorn, J., & Iovanna, J. (2009) · Pancreatology · doi:10.1159/000199435 · Cited by 39
“However, although there has been at least one report of a c-Src-activating mutation present in human colon cancer [”
BackgroundSrc tyrosine kinase as a chemotherapeutic target: is there a clinical case?
Chen, T., George, J. A., & Taylor, C. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200602000-00002 · Cited by 42
Src inhibitors in breast cancer therapy
Hiscox, S., & Nicholson, R. I. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.6.757 · Cited by 37
“In breast cancer tissue, elevated Src activity is frequently reported relative to normal breast tissue [17-19] ; this probably arises from deregulated Src protein expression and/or regulation [7] rather than genetic activation, since mutations in Src in cancer are rarely reported [20-23] .”
BackgroundA novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model
Serrels, B., Serrels, A., Mason, S. M., Baldeschi, C., Ashton, G. H. S., Canel, M., Mackintosh, L. J., Doyle, B. J., Green, T. P., Frame, M. C., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn278 · Cited by 39
N-acetyl-l-cysteine fosters inactivation and transfer to endolysosomes of c-Src
Krasnowska, E. K., Pittaluga, E., Brunati, A. M., Brunelli, R., Costa, G., Spirito, M. D., Serafino, A., Ursini, F., & Parasassi, T. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.012 · Cited by 37
Lack of Activating c-SRC Mutations at Codon 531 in Rectal Cancer
Nilbert, M. C., & Fernebro, E. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(00)00226-0 · Cited by 36
Suzuki, K., Oneyama, C., Kimura, H., Tajima, S., & Okada, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.195362 · Cited by 35
Src Family Tyrosine Kinases in Intestinal Homeostasis, Regeneration and Tumorigenesis
Sirvent, A., Mevizou, R., Naim, D., Lafitte, M., & Roche, S. (2020) · Cancers · doi:10.3390/cancers12082014 · Cited by 35
“Some oncogenic mutations for Src were previously reported in a small fraction of metastatic CRC [56], but these molecular alterations might not explain the frequent SFK deregulation observed in these cancers [49–51].”
BackgroundGelman, I. H. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.8264 · Cited by 37
“Although Src-family kinases are rarely mutated in human cancers [40, 41], there is growing appreciation that they play critical roles in cancer progression,”
BackgroundSrc, p130Cas, and Mechanotransduction in Cancer Cells
Matsui, H., Harada, I., & Sawada, Y. (2012) · Genes & Cancer · doi:10.1177/1947601912461443 · Cited by 36
“v-Src has a genomic deletion in the C-terminal region, promoting constitutive activation and high oncogenicity.(30) Myristoylation at the N-terminus of Src tethers it to the plasma membrane.”
BackgroundCell-cell and cell-matrix adhesion in survival and metastasis: Stat3 versus Akt
Niit, M., Hoskin, V., Carefoot, E., Geletu, M., Arulanandam, R., Elliott, B. E., & Raptis, L. H. (2015) · BioMolecular Concepts · doi:10.1515/bmc-2015-0022 · Cited by 38
“This results in cells that are more ‘sticky’ and do not migrate or invade, indicating that the role of FAK in FAs is complex (111).”
BackgroundInfluentialTumor necrosis factor α stimulates invasion of Src-activated intestinal cells
Kawai, N., Tsuji, S., Tsujii, M., Ito, T., Yasumaru, M., Kakiuchi, Y., Kimura, A., Komori, M., Sasaki, Y., Hayashi, N., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.31023 · Cited by 35
Hosoya, N., Qiao, Y., Hangaishi, A., Wang, L., Nannya, Y., Sanada, M., Kurokawa, M., Chiba, S., Hirai, H., & Ogawa, S. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20147 · Cited by 34
“Although Irby et al. (1999) *Correspondence to: Seishi Ogawa, Department of Hematology and Oncology, Department of Regeneration Medicine for Hematopoiesis, Graduate School of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.”
BackgroundMa, S., & Rubin, B. P. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.13 · Cited by 33
Olszewska-Pazdrak, B., Townsend, C. M., & Hellmich, M. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400208200 · Cited by 33
Ezrin is key regulator of Src-induced malignant phenotype in three-dimensional environment
Heiska, L., Melikova, M., Zhao, F., Saotome, I., McClatchey, A. I., & Carpén, O. (2011) · Oncogene · doi:10.1038/onc.2011.207 · Cited by 32
“, 2002), but increased Src levels and activating mutations are detected as colon tumors progress (Talamonti et al., 1993; Cartwright et al., 1994; Mao et al., 1997; Irby et al., 1999).”
BackgroundSrcasm Corrects Fyn-induced Epidermal Hyperplasia by Kinase Down-regulation
Li, W., Marshall, C. M., Mei, L., Gelfand, J. M., & Seykora, J. T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606583200 · Cited by 33
Iterative Microarray and RNA Interference–Based Interrogation of the Src-Induced Invasive Phenotype
Irby, R., Malek, R. L., Bloom, G., Tsai, J., Letwin, N. E., Frank, B. C., Verratti, K. J., Yeatman, T. J., & Lee, N. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3609 · Cited by 33
“1B) indicative of high metastatic potential (23).”
Self-citationBhattacharjee, P. S., Huq, T. S., Mandal, T. K., Graves, R. A., Muniruzzaman, S., Clément, C., McFerrin, H. E., & Hill, J. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015905 · Cited by 31
“cSrc [27,28], FAK [28], Akt [29], ERK1/2 [30] and eNOS [31]”
Wadhawan, A., Smith, C. R., Nicholson, R. I., Barrett-Lee, P. J., & Hiscox, S. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.08.003 · Cited by 31
Yamaguchi, H., Woods, N. T., Dorsey, J. F., Takahashi, Y., Gjertsen, N., Yeatman, T. J., Wu, J., & Wang, H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709882200 · Cited by 31
Self-citationLauzier, A., Charbonneau, M., Harper, K., Jilaveanu-Pelmus, M., & Dubois, C. M. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30305 · Cited by 31
Khoury, T., Arshad, A., Bogner, P. N., Ramnath, N., Zhang, S., Chandrasekhar, R., Wilding, G. E., Alrawi, S., & Tan, D. (2009) · CHEST Journal · doi:10.1378/chest.08-2482 · Cited by 31
pp60cSrc Is a Caspase-3 Substrate and Is Essential for the Transformed Phenotype of A431 Cells
Karni, R., & Levitzki, A. (2000) · Molecular Cell Biology Research Communications · doi:10.1006/mcbr.2000.0197 · Cited by 31
Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells
Gaule, P., Mukherjee, N., Corkery, B., Eustace, A. J., Gately, K. A., Roche, S., O'Connor, R. A., O'Byrne, K. J., Walsh, N., Duffy, M. J., et al. (2019) · Cancers · doi:10.3390/cancers11040548 · Cited by 32
“To determine if a mutation in the active site of Src kinase may be causing constitutive activation of p-Src, in the presence of dasatinib, we sequenced exons 9–12 of the Src gene, which encompass tyrosine 419 and the regulatory site at tyrosine 530 [19,20], in both the MDA-MB-231 parental and 231DasB cells.”
BackgroundKunte, D. P., Wali, R. K., Koetsier, J. L., Hart, J. A. L., Kostjukova, M. N., Kilimnik, A. Y., Pyatkin, I. G., Strelnikova, S. R., & Roy, H. K. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.05.030 · Cited by 30
“Several mechanisms have been proposed for Src activation in colon cancers including activating mutations (seen in 12% of CRC) [20], transcriptional overexpression”
BackgroundWillems, S. M., Schrage, Y. M., Bruijn, I. H. B., Szuhai, K., Hogendoorn, P. C. W., & Bovée, J. V. M. G. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-257 · Cited by 32
“Src plays an important role in embryonic development, cell growth and cell survival and activating mutations in Src have been reported in colorectal carcinoma [47,48].”
Pathways of metastasis suppression in bladder cancer
Said, N. A., & Theodorescu, D. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9197-4 · Cited by 29
“Discrepancies between the levels of c-Src protein expression and activity and the grade and stages of the tumor cells have been found in some colorectal tumors and have been explained by the presence of overexpressed receptor tyrosine kinases such as EGFR in poorly differentiated tumors, which can activate c-Src compe…”
BackgroundPharmacogenetics and biomarkers in colorectal cancer
Strimpakos, A. S., Syrigos, K. N., & Saif, M. W. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.8 · Cited by 32
Nasir, A., Kaiser, H. E., Boulware, D. C., Hakam, A., Zhao, H., Yeatman, T. J., Barthel, J. S., & Coppola, D. (2004) · Clinical Colorectal Cancer · doi:10.3816/ccc.2004.n.005 · Cited by 29
Self-citationThe COOH-terminal Src kinase Csk is a tumor antigen in human carcinoma.
Bénistant, C., Bourgaux, J.-F., Chapuis, H., Mottet, N., Roche, S., & Balì, J.-P. (2001) · PubMed · Cited by 30
Src-family tyrosine kinases as therapeutic targets in advanced cancer
Gelman, I. H. (2011) · Frontiers in Bioscience · doi:10.2741/e287 · Cited by 28
Danson, S. J., Mulvey, M. R., Turner, L., Horsman, J. M., Escott, K. J., Coleman, R. E., Ahmedzai, S. H., Bennett, M., & Andrew, D. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100261 · Cited by 28
“However, the only human diseases that implicate abnormal Src function in their pathogenesis are a subset of advanced colon cancers that were metastatic to the liver [52] as well as thrombocytopenia-6 [53], and as yet there is no evidence for a role of abnormal Src function in clinical pain in patients.”
BackgroundKalakonda, S., Nallar, S. C., Gong, P., Lindner, D. J., Goldblum, S. E., Reddy, S. P., & Kalvakolanu, D. V. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070241 · Cited by 30
“These observations may also be important in light of the fact that some advanced human colon carcinomas possess an activated mutant version of src.(80) Interestingly, a metabolic regulatory enzyme PDK4 is also repressed by Src, and GRIM-19 restored its expression.”
BackgroundSato, K., Iwasaki, T., Hirahara, S., Nishihira, Y., & Fukami, Y. (2003) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.017 · Cited by 29
Synthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives
Chand, K., Prasad, S., Tiwari, R. K., Shirazi, A. N., Kumar, S., Parang, K., & Sharma, S. K. (2014) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2014.02.001 · Cited by 28
“Increased Src activity elevates the cell growth rate and reduces adhesion between cells, leading to the development of metastatic potential of cells [7-9].”
BackgroundStenzinger, A., Schreiner, D., Reiners-Koch, P.-S., Hofer, H. W., & Wimmer, M. A. (2009) · International review of cytology · doi:10.1016/s1937-6448(09)75006-3 · Cited by 31
Lin, E. H., Hui, A. Y., Meens, J., Tremblay, E. A., Schaefer, E., & Elliott, B. E. (2003) · Experimental Cell Research · doi:10.1016/j.yexcr.2003.09.008 · Cited by 28
Yamaguchi, K., Kugimiya, T., & Miyazaki, T. (2005) · Brain Tumor Pathology · doi:10.1007/s10014-005-0178-1 · Cited by 28
“More recently, an activating mutation in c-Src was revealed in a subset of advanced human colon cancers.(35) Based on these data, c-Src inhibitors are being evaluated as anticancer agents.”
BackgroundPrice, D. J., & Jorgensen, W. L. (2001) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1012266200343 · Cited by 28
Decreased CHK protein levels are associated with Src activation in colon cancer cells
Zhu, S., Bjorge, J. D., Cheng, H., & Fujita, D. (2007) · Oncogene · doi:10.1038/sj.onc.1210838 · Cited by 27
“%) of advanced human colon cancer specimens in which Src activation has been attributed by a truncation mutation in Src (Irby et al., 1999).”
BackgroundSelf-citationRathore, V., Okada, M., Newman, P. J., & Newman, D. K. (2007) · Biochemical Journal · doi:10.1042/bj20061618 · Cited by 27
Boudný, V., & Nakano, S. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600080 · Cited by 27
“Specifically, c-Src has been found to be highly activated in colon cancer metastasized to the liver (Mao et al, 1997) and mutation in the regulatory domain of c-Src has been reported as a mechanism of Src activation in human colon cancer (Irby et al, 1999).”
BackgroundExome sequencing in 51 early onset non‐familial CRC cases
Thutkawkorapin, J., Lindblom, A., & Tham, E. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.605 · Cited by 27
“, 2014) and may have a role in colon cancer progression (Irby et al., 1999).”
BackgroundEGFR–c-Src-Mediated HDAC3 Phosphorylation Exacerbates Invasion of Breast Cancer Cells
Kwak, S., Seo, J., Hwang, J.-T., Sung, G., Song, J., Jeong, J., Lee, S., Yoon, H., Choi, H., & Choi, K. (2019) · Cells · doi:10.3390/cells8080930 · Cited by 30
“Elevated protein levels and/or the catalytic activity of c-Src have been detected in several human cancers, including lung, skin, colon, breast, ovarian, endometrial, and head and neck cancers [12,13].”
BackgroundCorrelation between Mcl-1 and pAKT protein expression in colorectal cancer.
Henderson‐Jackson, E., Helm, J. F., Ghayouri, M., Hakam, A., Nasir, A., Leon, M., Bui, M. M., Yeatman, T. J., & Coppola, D. (2010) · PubMed Central · Cited by 26
Self-citationRajala, R. V. S., Dehm, S. M., Bi, X., Bonham, K., & Sharma, R. K. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3066 · Cited by 26
Targeting Protein Kinases for Tumor Therapy
Sachsenmaier, C. (2001) · Oncology Research and Treatment · doi:10.1159/000055106 · Cited by 38
Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia
Sagatys, E. M., Garrett, C. R., Boulware, D. C., Kelley, S., Malafa, M. P., Cheng, J. Q., Sebti, S. M., & Coppola, D. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.03.003 · Cited by 25
Self-citationPervanadate stabilizes desmosomes
Garrod, D. R., Fisher, C., Smith, A. K., & Nie, Z. (2008) · Cell Adhesion & Migration · doi:10.4161/cam.2.3.6549 · Cited by 25
Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans
Wang, H., Liu, B., Al-Aidaroos, A. Q., Shi, H., Li, L., Guo, K., Li, J., Tan, B., Loo, J. M., Tang, J. P., et al. (2015) · Oncogene · doi:10.1038/onc.2015.391 · Cited by 25
Genetic profiling of colon cancer
Neibergs, H. L., Hein, D. W., & Spratt, J. S. (2002) · Journal of Surgical Oncology · doi:10.1002/jso.10131 · Cited by 27
“Src, a cytoplasmic protein-tyrosine kinase, has been associated with colon cancer through the detection of a truncating mutation in a tumor specimen [62].”
BackgroundYao, Q., Liu, B., Li, H., McGarrigle, D. K., Xing, B., Zhou, M., Wang, Z., Zhang, J. J., Huang, X., & Guo, L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.546481 · Cited by 24
“Human oncogenic alleles of Src kinases have been identified (11).”
BackgroundA p130 Cas tyrosine phosphorylated substrate domain decoy disrupts v-Crk signaling
Kirsch, K. H., Kensinger, M. H., Hanafusa, H., & August, A. (2002) · BMC Cell Biology · doi:10.1186/1471-2121-3-18 · Cited by 24
“Indeed, colon cancer cells with high metastatic potential have elevated levels of Src activity or activating mutations in the Src gene [4,5].”
Backgroundp70S6K is regulated by focal adhesion kinase and is required for Src-selective autophagy
Sandilands, E., Schoenherr, C., & Frame, M. C. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.05.017 · Cited by 24
Novel Protein Kinase Inhibitors: SMART Drug Design Technology
Sawyer, T. K., Bohacek, R. S., Metcalf, C. A., Shakespeare, W. C., Wang, Y., Sundaramoorthi, R., Keenan, T. P., Narula, S. S., Weigele, M., & Dalgarno, D. C. (2003) · BioTechniques · doi:10.2144/sawyerjun03revised · Cited by 24
Fer tyrosine kinase oligomer mediates and amplifies Src-induced tumor progression
Oneyama, C., Yoshikawa, Y., Ninomiya, Y., Iino, T., Tsukita, S., & Okada, M. (2015) · Oncogene · doi:10.1038/onc.2015.110 · Cited by 23
Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma
de la Puente, P., Azab, F., Muz, B., Luderer, M. J., Arbiser, J. L., & Azab, A. K. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1099645 · Cited by 24
“In addition, an activating mutation (Src 531) in human colon cancers with high Src activity suggests the oncogenic potential of Src [16].”
Coupling kinase activation to substrate recognition in SRC-family tyrosine kinases
Pellicena, P., & Miller, W. T. (2002) · Frontiers in bioscience · doi:10.2741/a725 · Cited by 26
Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09344-3 · Cited by 22
“Previously, our laboratory was the first to document that human CRC truncating mutations in the negative regulatory domain of SRC result in SRC activation [20].”
BackgroundSelf-citationTargeting the Rna-Binding Protein Sam68 As A Treatment For Cancer?
Lukong, K. E., & Richard, S. (2007) · Future Oncology · doi:10.2217/14796694.3.5.539 · Cited by 22
“Src kinase activity is also elevated in several epithelial cancers [37] including cancers of the breast [46,47] and the colon [48].”
BackgroundLi, L., Cui, Y., Shen, J., Dobson, H. E., & Sun, G. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.01.006 · Cited by 22
“However, naturally occurring SFK activation by mutations as a cause of cancer is rare [53-56].”
BackgroundDeterminants of the tumor suppressor INPP4B protein and lipid phosphatase activities
Lopez, S. M., Hodgson, M. C., Packianathan, C., Özakpınar, Ö. B., Uras, F., Rosen, B. P., & Agoulnik, I. U. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.09.077 · Cited by 27
“Constitutively active Src was obtained by PCR amplification (ACCCAAGCTG GCTAGCACCATGGG TAGCAACAAGA, AAGTTTAAACGCTAGCCTAGTACTGGGGCTCGGT) of Src [16] from PC-3 cells and insertion into pCR3.”
Metadata
- Authors
- Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., & Yeatman, T. J.
- Affiliations
- University of South Florida (US)
- University of Calgary (CA)
- Corresponding author
- Yeatman, Timothy J.
- Venue
- Nature Genetics
- Published
- 1999-02
- Volume
- 21
- Issue
- 2
- Pages
- 187-190
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- DOI
- 10.1038/5971
- OpenAlex
- W1594706458
- Cited by
- 489
- References
- 28
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 2 · 2023: 11 · 2022: 1 · 2021: 5 · 2020: 9 · 2019: 13 · 2018: 9 · 2017: 9 · 2016: 12 · 2015: 15 · 2014: 19 · 2013: 12 · 2012: 21
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- TSpace (University of Toronto) (submittedVersion)
- Funders
- National Institutes of Health (5k11ca065512-03)
- National Cancer Institute (R01CA055652, CA-55652, CA65512)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- Src kinase, colon cancer, truncating mutations, non-receptor tyrosine kinase, oncogenic transformation, carcinogenesis, liver metastasis, malignant progression, Rous sarcoma virus
- MeSH terms
- Animals, Cell Line, Colonic Neoplasms, Humans, Liver Neoplasms, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Mutation, Neoplasm Transplantation, Transfection, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, Genes, src, Proto-Oncogene Proteins pp60(c-src), 3T3 Cells, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.